Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384449 · ClinicalTrials.gov registry record · Phase 2
Lucentis (Ranibizumab) for Eales' Disease
A Phase 2 study of Eales' Disease, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT00384449: Completed Phase 2 study of Eales' Disease, sponsored by Oregon Health and Science University.
NCT00384449 is a Phase 2 study of Eales' Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00384449, a Phase 2 study of Eales' Disease, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Oregon
- Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00384449 record still lists
NCT00384449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Eales' Disease appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00384449 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00384449 about?
NCT00384449 is a clinical study titled "Lucentis (Ranibizumab) for Eales' Disease". The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given...
What is the current status of trial NCT00384449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2006-10. Estimated completion is 2009-04.
What conditions does trial NCT00384449 study?
This clinical trial studies the following conditions: Eales' Disease.
What interventions are being tested in trial NCT00384449?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00384449?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00384449 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00384449's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia